A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.

ABSTRACT:

Objective

The objective was to test the clinical utility of Quantose M(Q) to monitor changes in insulin sensitivity after pioglitazone therapy in prediabetic subjects. Quantose M(Q) is derived from fasting measurements of insulin, α-hydroxybutyrate, linoleoyl-glycerophosphocholine, and oleate, three nonglucose metabolites shown to correlate with insulin-stimulated glucose disposal.

Research design and methods

Participants were 428 of the total of 602 ACT NOW impaired glucose tolerance (IGT) subjects randomized to pioglitazone (45 mg/d) or placebo and followed for 2.4 years. At baseline and study end, fasting plasma metabolites required for determination of Quantose, glycated hemoglobin, and oral glucose tolerance test with frequent plasma insulin and glucose measurements to

SUBMITTER: Tripathy D 

PROVIDER: S-EPMC4422894 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature